Abstract
Digital technologies are changing numerous industries in a very short time, especially the healthcare sector. Many established companies want to become digital themselves. Our paper gives a brief overview of patterns of digital business model observed in the big pharmaceutical companies. The patterns vary in the degree of digitalization of the products and services, the value creating activities that can be in collaboration with technology firms or even competitors and the target of the product with regard to main milestones of the patient’s medical journey. The results of the study are not limited to big pharmaceutical companies. The authors recommend the application of the results to other types of companies in the pharmaceutical industry and in other industries.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Change history
23 October 2019
In the originally published version of this chapter, the name of the fourth author Herwig Winkler was incorrect. The name of the author has been corrected.
References
Gassmann, O., Frankenberger, K., Sauer, R.: Exploring the Field of Business Model Innovation: New Theoretical Perspectives. Palgrave Pivot. Palgrave Macmillan, Cham (2016)
Osterwalder, A., Pigneur, Y.: Business Model Generation: A Handbook for Visionaries, Game Changers, and Challengers. Wiley, Hoboken (2010)
Abdelkafi, N., Makhotin, S., Posselt, T.: Business model innovations for electric mobility: what can be learned from existing business model patterns? Int. J. Innov. Manag. 17(01), 1340003 (2013). https://doi.org/10.1142/s1363919613400033
Remane, G., Hanelt, A., Tesch, J.F., et al.: The business model pattern database—: a tool for systematic business model innovation. Int. J. Innov. Manag. 21(01), 1750004 (2017). https://doi.org/10.1142/s1363919617500049. (61 Pages)
Gassmann, O., Frankenberger, K., Csik, M.: The Business Model Navigator: 55 Models that Will Revolutionise Your Business. Pearson, Harlow (2014)
Sprenger, M., Mettler, T.: On the utility of e-health business model design patterns. In: 24th European Conference on Information Systems (ECIS) 2016. Bogaziçi University, Istanbul, Turkey, pp. 1–16 (2016)
Sprenger, M.: Supporting the viability of e-health services with pattern-based business model design. In: Li, H., Nykänen, P., Suomi, R., Wickramasinghe, N., Widén, G., Zhan, M. (eds.) WIS 2016. CCIS, vol. 636, pp. 161–175. Springer, Cham (2016). https://doi.org/10.1007/978-3-319-44672-1_14
Foss, N.J., Saebi, T.: Fifteen years of research on business model innovation. JOM 43(1), 200–227 (2017). https://doi.org/10.1177/0149206316675927
Bohnsack, R., Pinkse, J., Kolk, A.: Business models for sustainable technologies: exploring business model evolution in the case of electric vehicles. Res. Policy 43(2), 284–300 (2014). https://doi.org/10.1016/j.respol.2013.10.014
Mehralian, G., Rajabzadeh Gatari, A., Morakabati, M., et al.: Developing a suitable model for supplier selection based on supply chain risks: an empirical study from Iranian pharmaceutical companies. Iran J. Pharm. Res. 11(1), 209–219 (2012)
Sabatier, V., Mangematin, V., Rousselle, T.: From recipe to dinner: business model portfolios in the European biopharmaceutical industry. Long Range Plan. 43(2–3), 431–447 (2010). https://doi.org/10.1016/j.lrp.2010.02.001
Chalkidou, K., Tunis, S., Lopert, R., et al.: Comparative effectiveness research and evidence-based health policy: experience from four countries. Milbank Q. 87(2), 339–367 (2009). https://doi.org/10.1111/j.1468-0009.2009.00560.x
Gassmann, O., Reepmeyer, G., Zedtwitz, M.: Leading pharmaceutical innovation: trends and drivers for growth in the pharmaceutical industry, 2nd edn. Springer, Heidelberg (2008). https://doi.org/10.1007/978-3-540-77636-9
Schuhmacher, A., Gassmann, O., Hinder, M.: Changing R&D models in research-based pharmaceutical companies. J. Transl. Med. 14(1), 105 (2016). https://doi.org/10.1186/s12967-016-0838-4
Lee, M., Ly, H., Möller, C.C., et al.: Innovation in regulatory science is meeting evolution of clinical evidence generation. Clin. Pharmacol. Ther. 105, 886–898 (2019). https://doi.org/10.1002/cpt.1354
Pinto, M.D., Greenblatt, A.M., Hickman, R.L., et al.: Assessing the critical parameters of eSMART-MH: a promising avatar-based digital therapeutic intervention to reduce depressive symptoms. Perspect. Psychiatr. Care 52(3), 157–168 (2016). https://doi.org/10.1111/ppc.12112
Sverdlov, O., van Dam, J., Hannesdottir, K., et al.: Digital therapeutics: an integral component of digital innovation in drug development. Clin. Pharmacol. Ther. 104(1), 72–80 (2018)
Inc A HealthKit - Apple Developer. https://developer.apple.com/healthkit/. Accessed 15 Feb 2019
Rodarte, C.: Pharmaceutical perspective: how digital biomarkers and contextual data will enable therapeutic environments. Digit Biomark. 1, 73–81 (2017). https://doi.org/10.1159/000479951
Smith, B., Sverdlov, A.: Digital technology: the future is bright. Clin. Pharmacol. Ther. 104(1), 9–11 (2018)
Robert Wood Johnson Foundation: Assessment Report (2013). https://www.rwjf.org/en/library/research/2013/12/2013-assessment-report.html. Accessed 15 Feb 2019
Ernst & Young Global Limited: How to manage disruptions to gain competitive advantage (2017). https://www.ey.com/en_gl/life-sciences/how-to-manage-disruptions-to-gain-competitive-advantage. Accessed 15 Feb 2019
Koen, P.A., Bertels, H.M.J., Elsum, I.R.: The three faces of business model innovation: challenges for established firms. Res. Technol. Manag. 54(3), 52–59 (2011). https://doi.org/10.5437/08953608x5403009
Chesbrough, H.: Business model innovation: opportunities and barriers. Long Range Plan. 43(2–3), 354–363 (2010). https://doi.org/10.1016/j.lrp.2009.07.010
Chesbrough, H., Rosenbloom, R.S.: The role of business model in capturing value from innovation: evidence from Xerox Corporation’s technology spinn-off companies, 11(3), 529–555 (2002)
Magretta, J.: Why business models Matter. Harv. Bus. Rev. 80(5), 86–92 (2002)
Osterwalder, A., Pigneur, Y., Tucci, C.L.: Clarifying business models: origins, present, and future of the concept. Commun. Assoc. Inf. Syst. (15), 1–43 (2005)
Shafer, S.M., Smith, H.J., Linder, J.C.: The power of business models. Bus. Horiz. 48(3), 199–207 (2005). https://doi.org/10.1016/j.bushor.2004.10.014
Schallmo, D., Brecht, L.: Business model innovation in business-to-business markets -: procedure and examples. Paper presented at the 3rd ISPIM Innovation Symposium: “Managing the Art of Innovation: Turning Concepts into Reality”, Quebec City, Canada (2010)
Spieth, P., Schneckenberg, D., Ricart, J.E.: Business model innovation - state of the art and future challenges for the field. R&D Manag. 44(3), 237–247 (2014). https://doi.org/10.1111/radm.12071
Morris, M.H., Shirokova, G., Shatalov, A.: The business model and firm performance: the case of russian food service ventures. JSBM 51(1), 46–65 (2013)
Wikipedia: List of largest pharmaceutical companies by revenue – Wikipedia (2019). https://en.wikipedia.org/w/index.php?oldid=883348703. Accessed 14 Feb 2019
Top 50 Global Pharma Companies - 2018 (Pharmaceutical Executive)—Ranking The Brands. https://www.rankingthebrands.com/The-Brand-Rankings.aspx?rankingID=370. Accessed 14 Feb 2019
Health Care Companies. https://www.nasdaq.com/screening/companies-by-industry.aspx?industry=Health+Care. Accessed 14 Feb 2019
Bryman, A., Bell, E.: Business Research Methods, 3rd edn. Oxford University Press, Oxford (2011)
Hsieh, H.-F., Shannon, S.E.: Three approaches to qualitative content analysis. Qual. Health Res. 15(9), 1277–1288 (2005). https://doi.org/10.1177/1049732305276687
Camisón, C., Villar-López, A.: Business models in Spanish industry: a taxonomy-based efficacy analysis. M@n@gement 13(4), 298 (2010). https://doi.org/10.3917/mana.134.0298
Communications BAG FDA grants breakthrough device designation to artificial intelligence software for CTEPH pattern recognition from Bayer and MSD - Bayer News. https://media.bayer.com/baynews/baynews.nsf/id/FDA-grants-breakthrough-device-designation-artificial-intelligence-software-CTEPH-pattern. Accessed 14 Feb 2019
ORILISSA™ (elagolix) 150 mg or 200 mg Tablets (2019). https://www.orilissa.com/about/what-is-orilissa. Accessed 15 Feb 2019
Mobihealthnews: FDA’s new draft guidance could hinder applications for digital combination products (2019). https://www.mobihealthnews.com/content/fdas-new-draft-guidance-could-hinder-applications-digital-combination-products. Accessed 15 Feb 2019
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Appendices
Appendix 1
Dendrogram of a cluster analysis of 53 digital business models of pharmaceutical products from nine top pharmaceutical companies.
Appendix 2
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this paper
Cite this paper
Tangour, C., Gebauer, M., Fischer, L., Winkler, H. (2019). Digital Business Model Patterns of Big Pharmaceutical Companies - A Cluster Analysis. In: Jallouli, R., Bach Tobji, M., Bélisle, D., Mellouli, S., Abdallah, F., Osman, I. (eds) Digital Economy. Emerging Technologies and Business Innovation. ICDEc 2019. Lecture Notes in Business Information Processing, vol 358. Springer, Cham. https://doi.org/10.1007/978-3-030-30874-2_31
Download citation
DOI: https://doi.org/10.1007/978-3-030-30874-2_31
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-30873-5
Online ISBN: 978-3-030-30874-2
eBook Packages: Computer ScienceComputer Science (R0)